StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals operating margin

Operating margin is operating income as a percentage of revenue.

Provectus Biopharmaceuticals's operating margin for the twelve months ending Dec 31, 2025 was -1575.3%. For fiscal 2025 it was -1575.3%, against -734.4% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1575.3%−840.9
FY2024Dec 31, 2024-734.4%−214.2
FY2023Dec 31, 2023-520.2%−173.6
FY2022Dec 31, 2022-346.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2025Jun 30, 2025-3132.8%−2821.1
Q1 FY2025Mar 31, 2025-394.1%−206.2
Q4 FY2024Dec 31, 2024-16289.0%−15789.7
Q3 FY2024Sep 30, 2024-870.9%+153.3
Q2 FY2024Jun 30, 2024-311.7%+182.7
Q1 FY2024Mar 31, 2024-187.9%+193.7
Q4 FY2023Dec 31, 2023-499.3%−84.5
Q3 FY2023Sep 30, 2023-1024.1%−812.6
Q2 FY2023Jun 30, 2023-494.4%−159.4
Q1 FY2023Mar 31, 2023-381.5%+151.5
Q4 FY2022Dec 31, 2022-414.8%–
Q3 FY2022Sep 30, 2022-211.6%–
Q2 FY2022Jun 30, 2022-335.1%–
Q1 FY2022Mar 31, 2022-533.1%–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?